|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...3940414243444546474849...156157» |
- Enrollment closed, Trial primary completion date: Effects of Cognitive Behavioural Therapy and Exercise on Stress and Cognitive Deficits in Multiple Sclerosis (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=173, Active, not recruiting, Sponsor: Sunnybrook Health Sciences Centre
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jun 2016
- || SAR438544 / Sanofi
Trial primary completion date: A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients (clinicaltrials.gov) - Apr 14, 2016
P1, N=70, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Mar 2016 --> Jun 2016
- |||| Enrollment open, Trial initiation date: Effect of Fingolimod on Neurodegeneration (clinicaltrials.gov) - Apr 14, 2016
P4, N=120, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2016 --> Jun 2016 Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Feb 2016
- ||| Ruxience (rituximab-pvvr) / Pfizer
Trial completion: Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04) (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=184, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Feb 2016 Active, not recruiting --> Completed
- | GZ402668 / Sanofi
Trial completion: A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Apr 13, 2016
P1, N=48, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial completion: SARIL-RA-EASY: To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 13, 2016
P3, N=217, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Orencia (abatacept) / BMS
Trial initiation date: Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL (clinicaltrials.gov) - Apr 13, 2016
P=N/A, N=370, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Initiation date: Mar 2014 --> Sep 2013
- dimethyl fumarate / Generic mfg.
Enrollment change, Trial withdrawal: Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Apr 13, 2016
P3, N=0, Withdrawn, Sponsor: Biogen
Initiation date: Mar 2014 --> Sep 2013 N=172 --> 0 | Not yet recruiting --> Withdrawn
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Clinical: Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Apr 13, 2016
P2, N=48, Recruiting, Sponsor: Boehringer Ingelheim
N=172 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
Trial completion: An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 12, 2016
P2, N=49, Completed, Sponsor: Samsung Bioepis Co., Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| dimethyl fumarate / Generic mfg.
Trial completion: TOLERATE: Gastrointestinal Tolerability Study Of Dimethyl Fumarate (DMF) In Participants With Relapsing-Remitting Multiple Sclerosis In Germany (clinicaltrials.gov) - Apr 12, 2016
P4, N=214, Completed, Sponsor: Biogen
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment closed, Enrollment change, Trial primary completion date: LADA: Genetics of Latent Autoimmune Diabetes in Adults (clinicaltrials.gov) - Apr 12, 2016
P=N/A, N=205, Active, not recruiting, Sponsor: Children's Hospital of Philadelphia
Recruiting --> Completed Recruiting --> Active, not recruiting | N=10000 --> 205 | Trial primary completion date: Mar 2017 --> Nov 2015
- Enrollment closed, Trial primary completion date: To Evaluate if Wide Blood Sugar Fluctuations Lead to Injury of Heart Function and Heart Nerves (clinicaltrials.gov) - Apr 12, 2016
P=N/A, N=55, Active, not recruiting, Sponsor: University of Michigan
Recruiting --> Active, not recruiting | N=10000 --> 205 | Trial primary completion date: Mar 2017 --> Nov 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Aug 2016
- | Trial completion, Enrollment change: A Randomised Trial Comparing Anterior Versus Posterior Approach in Total Hip Replacement (clinicaltrials.gov) - Apr 12, 2016
P=N/A, N=50, Completed, Sponsor: Medacta International SA
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Aug 2016 Recruiting --> Completed | N=100 --> 50
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion, Enrollment change, Trial primary completion date, HEOR: Health-related Quality of Life Measure in Pediatric Lupus (clinicaltrials.gov) - Apr 12, 2016
P=N/A, N=31, Completed, Sponsor: Rutgers, The State University of New Jersey
Recruiting --> Completed | N=100 --> 50 Active, not recruiting --> Completed | N=100 --> 31 | Trial primary completion date: Dec 2015 --> Nov 2012
- | Calquence (acalabrutinib) / AstraZeneca
Enrollment closed, Enrollment change, Trial primary completion date: ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate (clinicaltrials.gov) - Apr 11, 2016
P2, N=31, Active, not recruiting, Sponsor: Acerta Pharma BV
Active, not recruiting --> Completed | N=100 --> 31 | Trial primary completion date: Dec 2015 --> Nov 2012 Recruiting --> Active, not recruiting | N=70 --> 31 | Trial primary completion date: Jan 2017 --> May 2016
- |||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Trial completion, Trial primary completion date: Extension Study of MT-1303 (clinicaltrials.gov) - Apr 11, 2016
P2, N=367, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Active, not recruiting | N=70 --> 31 | Trial primary completion date: Jan 2017 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Mar 2016
- || Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: Clinical Disease Activity With Long Term Natalizumab Treatment (clinicaltrials.gov) - Apr 11, 2016
P=N/A, N=300, Recruiting, Sponsor: Biogen
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Mar 2016 Trial primary completion date: Feb 2016 --> May 2016
- Trial completion: Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting (clinicaltrials.gov) - Apr 11, 2016
P=N/A, N=9, Completed, Sponsor: William Sansum Diabetes Center
Trial primary completion date: Feb 2016 --> May 2016 Recruiting --> Completed
- dimethyl fumarate / Generic mfg.
Trial primary completion date, IO biomarker: Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS (clinicaltrials.gov) - Apr 11, 2016
P4, N=45, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Completed Trial primary completion date: Jan 2018 --> Apr 2018
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, Patient reported outcomes: Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) (clinicaltrials.gov) - Apr 9, 2016
P=N/A, N=24, Terminated, Sponsor: Biogen
N=240 --> 24 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Mar 2016; 109MS415 ImPROve study was terminated due to patient enrollment challenges and feasibility . The decision was not a result of safety concerns.
- Trial completion: Overnight Type 1 Diabetes Control Under MD-Logic Closed Loop System at the Patient's Home (clinicaltrials.gov) - Apr 8, 2016
P=N/A, N=75, Completed, Sponsor: Rabin Medical Center
The decision was not a result of safety concerns. Active, not recruiting --> Completed
- ||||||| NI-071 (infliximab biosimilar) - Sanofi, Nichi / Iko, Binex, Aprogen, Elea Labs
Trial completion: A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 8, 2016
P3, N=242, Completed, Sponsor: Nichi-Iko Pharmaceutical Co.,Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New trial, HEOR: Effect of Qi Gong Training on Quality of Life in Patients With Systemic Lupus Erythematous (LuQi) (clinicaltrials.gov) - Apr 8, 2016
P=N/A, N=40, Not yet recruiting, Sponsor: University Hospital, Limoges
- | Enrollment open, Enrollment change, Trial initiation date, Trial primary completion date, Stroma: Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis (clinicaltrials.gov) - Apr 8, 2016
P1/2, N=50, Recruiting, Sponsor: Ageless Regenerative Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | N=10 --> 50 | Initiation date: Oct 2014 --> Apr 2016 | Trial primary completion date: Dec 2016 --> Apr 2017
- Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Trial primary completion date: SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=4, Terminated, Sponsor: St. Louis University
Not yet recruiting --> Recruiting | N=10 --> 50 | Initiation date: Oct 2014 --> Apr 2016 | Trial primary completion date: Dec 2016 --> Apr 2017 Trial primary completion date: Mar 2016 --> Dec 2016
- RNS60 / Revalesio
Enrollment change, Trial withdrawal: Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Apr 7, 2016
P2, N=0, Withdrawn, Sponsor: Revalesio Corporation
Trial primary completion date: Mar 2016 --> Dec 2016 N=270 --> 0 | Not yet recruiting --> Withdrawn
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P4 trial: Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS) (clinicaltrials.gov) - Apr 7, 2016
P4, N=74, Completed, Sponsor: Prof. Abid Z. Farooqi
- ||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed: A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Apr 7, 2016
P3, N=133, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=270 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- |||| dimethyl fumarate / Generic mfg., aspirin / Generic mfg.
Trial completion, P4 data: Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Apr 7, 2016
P4, N=241, Completed, Sponsor: Biogen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Zostavax (zoster vaccine live) / Merck (MSD)
Trial primary completion date: Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE) (clinicaltrials.gov) - Apr 7, 2016
P2, N=125, Recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed Trial primary completion date: Jan 2016 --> Jun 2016
- Trial primary completion date: The Role of Endogenous Lactate in Brain Preservation and Counterregulatory Defenses Against Hypoglycemia (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=30, Recruiting, Sponsor: Radboud University
Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Dec 2015 --> May 2016
- Trial primary completion date: CARBEX1: Impact of Physical Activity on Blood Glucose Stability and Energy Stores in Individuals With Type 1 Diabetes (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=27, Enrolling by invitation, Sponsor: University Hospital Inselspital, Berne
Trial primary completion date: Dec 2015 --> May 2016 Trial primary completion date: Mar 2016 --> Aug 2016
- | Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial completion, Enrollment change: Sarilumab Effect on the Pharmacokinetics of Simvastatin (clinicaltrials.gov) - Apr 7, 2016
P1, N=19, Completed, Sponsor: Sanofi
Trial primary completion date: Mar 2016 --> Aug 2016 Recruiting --> Completed | N=14 --> 19
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: RITACT: A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 (clinicaltrials.gov) - Apr 7, 2016
P4, N=26, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | N=14 --> 19 Trial primary completion date: Aug 2016 --> Apr 2016
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Apr 7, 2016
P3, N=15, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2016 --> Apr 2016 Trial primary completion date: Mar 2016 --> Jul 2015
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial termination: Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis (clinicaltrials.gov) - Apr 7, 2016
P1/2, N=3, Terminated, Sponsor: Eric B. Suhler
Trial primary completion date: Mar 2016 --> Jul 2015 Recruiting --> Terminated; insufficient enrollment
- Enrollment change, Trial withdrawal: Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes (clinicaltrials.gov) - Apr 7, 2016
P1, N=0, Withdrawn, Sponsor: Leilei Zhu
Recruiting --> Terminated; insufficient enrollment N=20 --> 0 | Recruiting --> Withdrawn
- New P3 trial: D-chiro-Inositol in Overweight Type 1 Diabetes Patients (clinicaltrials.gov) - Apr 7, 2016
P3, N=26, Completed, Sponsor: Campus Bio-Medico University
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open, Enrollment change, Trial initiation date: U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497) (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=300, Recruiting, Sponsor: Hoffmann-La Roche
N=20 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Recruiting | N=226 --> 300 | Initiation date: Aug 2012 --> Dec 2011
- ||||| Tavalisse (fostamatinib) / Rigel
Enrollment closed: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Apr 7, 2016
P3, N=75, Active, not recruiting, Sponsor: Rigel Pharmaceuticals
Active, not recruiting --> Recruiting | N=226 --> 300 | Initiation date: Aug 2012 --> Dec 2011 Recruiting --> Active, not recruiting
- ||| Trial completion: Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=223, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Completed
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice (clinicaltrials.gov) - Apr 6, 2016
P=N/A, N=413, Not yet recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Trial primary completion date: Jul 2018 --> Dec 2019
- |||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Clinical: Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) (clinicaltrials.gov) - Apr 6, 2016
P3, N=720, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Jul 2018 --> Dec 2019 Trial primary completion date: Dec 2016 --> Mar 2017
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Apr 6, 2016
P1, N=38, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Dec 2016 --> Mar 2017 Recruiting --> Active, not recruiting
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Apr 6, 2016
P=N/A, N=101, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date: Evolution of Effectiveness of Diabetes Medical Care in Russia (clinicaltrials.gov) - Apr 6, 2016
P=N/A, N=599, Completed, Sponsor: Endocrinology Research Centre, Moscow
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Apr 2016 --> Oct 2015
- |||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment open: Tocilizumab Real-Life Human Factors (RLHFs) Validation Study (clinicaltrials.gov) - Apr 6, 2016
P4, N=95, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: Apr 2016 --> Oct 2015 Not yet recruiting --> Recruiting
- New trial: Activity Limitations in Rheumatoid Arthritis (clinicaltrials.gov) - Apr 6, 2016
P=N/A, N=81, Completed, Sponsor: Federal University of Minas Gerais
- cyclophosphamide / Generic mfg.
New trial: Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome (clinicaltrials.gov) - Apr 6, 2016
P0, N=5, Not yet recruiting, Sponsor: Seah H Lim, MD, PhD